Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies, SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the toxicity profile, dose-limiting toxicity, maximum tolerated dose and pharmacokinetic profile of SP1049C, and to document any antitumour activity. The starting dose was 5 mg m(-2) (doxorubicin content) as an intravenous infusion once every 3 weeks for up to six cycles. A total of 26 patients received 78 courses at seven dose levels. The dose-limiting toxicity was myelosuppression and DLT was reached at 90 mg m(-2). The maximum tolerated dose was 70 mg m(-2) and is recommended for future trials. The pharmacokinetic profile of SP1049C showed a slower clearance than has been reported for conventional doxorubicin. Evidence of antitumour activity was seen in some patients with advanced resistant solid tumours. Phase II trials with this agent are now warranted to further define its antitumour activity and safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Side effects could be largely mitigated in both preclinical and clinical studies by using polymeric micelle formulations.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [17]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase I clinical trial, SP1049C exhibited a similar PK profile of doxorubicin to the conventional doxorubicin formulation and a similar MTD of 70 mg/m2 in the patients with metastatic or recurrent solid tumors [17].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SP1049C is a doxorubicin-loaded Pluronic®-based formulation which was developed by Supratek Pharma Inc. and was the first polymeric micelle drug formulation to enter clinical trials in 1999 [17].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Handbook of Pharmaceutical Excipients
Kibbe, A. H. (2003) · Medical Entomology and Zoology · Cited by 713
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 1×
“Liposomal drug delivery systems with doxorubicin have been extensively investigated in relapsed ovarian cancer (Muggia et al, 1997), breast cancer (Ranson et al, 1997) and others (Law et al, 1994; Schwartz and Caspar, 1995; Ellerhorst et al, 1999; Harrington et al, 2001; Judson et al, 2001).”
BackgroundPluronic® block copolymers for overcoming drug resistance in cancer
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00047-9 · Cited by 636 · cited 1×
“…including inhibition of drug efflux transporters, abolishment of drug sequestration in acidic compartments, inhibition of the glutathione (GSH)/glutathione (GST) detoxification system and reduction of ATP selectively in MDR cells (Venne et al, 1996; Batrakova et al, 2001; Kabanov et al, 2002).”
BackgroundSelf-citationMedical Applications of Liposomes
(1998) · Elsevier eBooks · doi:10.1016/b978-0-444-82917-7.x5000-5 · Cited by 416
Judson, I., Radford, J. A., Harris, M., Blay, J.-Y., van Hoesel, Q., le Cesne, A., van Oosterom, A. T., Clemons, M. J., Kamby, C., Hermans, C., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00050-8 · Cited by 392 · cited 1×
“Liposomal drug delivery systems with doxorubicin have been extensively investigated in relapsed ovarian cancer (Muggia et al, 1997), breast cancer (Ranson et al, 1997) and others (Law et al, 1994; Schwartz and Caspar, 1995; Ellerhorst et al, 1999; Harrington et al, 2001; Judson et al, 2001).”
BackgroundRanson, M. R., Carmichael, J., O'Byrne, K., Stewart, S., Smith, D., & Howell, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3185 · Cited by 293 · cited 3×
“…used to try and improve the therapeutic efficacy and toxicity profile of doxorubicin including the development of anthracycline analogues and the incorporation of anthracyclines into drug delivery vehicles, such as liposomes and polymeric drug conjugates (Ranson et al, 1997; Vasey et al, 1999).”
BackgroundMethodSelf-citationBlock copolymer-based formulation of doxorubicin. From cell screen to clinical trials
Alakhov, V., Klinski, E., Li, S., Pietrzynski, G., Venne, A., Batrakova, E., Bronitch, T., & Kabanov, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00064-8 · Cited by 266 · cited 4×
“Of particular note is the evidence of antitumour activity of SP1049C in doxorubicin-resistant tumours (Batrakova et al, 1996) and in multiple drug resistance (MDR) cells (Venne et al, 1996; Alakhov et al, 1999).”
BackgroundInfluentialSelf-citationBatrakova, E. V., Li, S., Elmquist, W. F., Miller, D. W., Alakhov, V. Y., & Kabanov, A. V. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2165 · Cited by 229 · cited 1×
“…including inhibition of drug efflux transporters, abolishment of drug sequestration in acidic compartments, inhibition of the glutathione (GSH)/glutathione (GST) detoxification system and reduction of ATP selectively in MDR cells (Venne et al, 1996; Batrakova et al, 2001; Kabanov et al, 2002).”
BackgroundSelf-citationBatrakova, E., Dorodnych, T., Klinskii, E., Kliushnenkova, E., Shemchukova, O., Goncharova, O., Arjakov, S., Alakhov, V., & Kabanov, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.587 · Cited by 228 · cited 2×
“Of particular note is the evidence of antitumour activity of SP1049C in doxorubicin-resistant tumours (Batrakova et al, 1996) and in multiple drug resistance (MDR) cells (Venne et al, 1996; Alakhov et al, 1999).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Lohri A, Gelmon KA, Embree L, Mayer L, Cullis P, Saletan S, Goldie J (1991) Phase I/II study of liposome encapsulated doxorubicin (TLC-D-99) in non small cell lung cancer. Proc Am Soc Clin Oncol 10: A292
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Metadata
- Authors
- Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M.
- Affiliations
- The Christie Hospital (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Supratek Pharma (Canada) (CA)
- Cancer Research UK (GB)
- University of Strathclyde (GB)
- Corresponding author
- Ranson, M
- Venue
- British Journal of Cancer
- Published
- 2004-05-04
- Volume
- 90
- Issue
- 11
- Pages
- 2085-2091
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2409484
- OpenAlex
- W2159334966
- Cited by
- 382
- References
- 20
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 17 · 2021: 7 · 2020: 18 · 2019: 13 · 2018: 11 · 2017: 22 · 2016: 26 · 2015: 26 · 2014: 26 · 2013: 32 · 2012: 26
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- doxorubicin, Pluronic block copolymers, advanced cancer, dose-limiting toxicity, myelosuppression, maximum tolerated dose, pharmacokinetics, antitumour activity, drug resistance, solid tumors
- MeSH terms
- Adult, Aged, Antibiotics, Antineoplastic, Doxorubicin, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasms, Polymers, Poloxamer, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6601856
- The paper
- Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004). Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6601856
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

